Quantcast

Latest Bendamustine Stories

2014-07-09 16:25:02

LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 https://www.reportbuyer.com/product/2225869/OpportunityAnalyzer-Chronic-Lymphocytic-Leukemia---Opportunity-Analysis-and-Forecasts-to-2018.html OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 SummaryChronic lymphocytic leukemia (CLL), the most common...

2014-06-23 12:29:37

BOCA RATON, Fla., June 23, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic version of Treanda® by Cephalon, Inc. On May 27, 2014, Cephalon, Inc. filed a Paragraph IV lawsuit against Breckenridge and its development and manufacturing partner Natco Pharma Limited in the United States District Court for the...

2014-05-14 16:29:31

- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin and JNJ-42756493 RARITAN, N.J., May 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...

2014-05-02 08:24:57

First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014. Financial Results for the Quarter Ended March 31, 2014 GAAP and Non-GAAP net income (loss) Non-GAAP net income reported for the quarter ended March 31, 2014 was $31.3 million, or $0.40 net income per diluted share,...

2014-04-10 12:24:44

Emerging Therapies are Not Expected to Offer Improvements in Safety and Tolerability Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European hematological oncologists' prescribing decisions for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...

2014-03-12 23:24:38

Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh, NC (PRWEB) March 12, 2014 According to the Non-Hodgkin’s Lymphoma Center, a study published in the journal Blood suggests that patients with certain kinds of Non-Hodgkin’s Lymphomas may get equally good results from a new chemotherapy combination than from the standard drugs. Researchers at the Sarah Cannon Research Institute...

2014-02-20 16:25:31

Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013. Financial Results for the Quarter and Year Ended December 31, 2013 Revenue Total revenue for the quarter ended December 31, 2013 increased 113% to $123.6 million, from $58.0 million for the...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related